HomeBUSINESS
BUSINESS

Biogen Japan Upbeat on Tecfidera, Near-Approval Nusinersen, Sakigake Boost for Aducanumab
(Jun.19.2017)

Biogen Japan President Shinichi Torii
Biogen Japan is on a roll. The company enjoys a strong uptake for its new multiple sclerosis (MS) med Tecfidera (dimethyl fumarate), while gearing up for an imminent green light for its spinal muscular atrophy (SMA) drug nusinersen. Aducanumab, an Alzheimer’s drug hopeful, is now in line for sped-up regulatory review ...
(LOG IN FOR FULL STORY)

Notice

 The next ebook update will be provided on August 28.

News Calendar